Efficacy and Safety Study of Combigan and 0.5% Timoptic in Normal Tension Glaucoma

• Status: Unknown status
• Trial end date: 2012-08-01
• Target enrollment: 0
• Participant gender: All

Summary

Purpose To evaluate efficacy and safety of combigan(Brimonidine/Timolol) and 0.5% Timoptic (Timolol) ophthalmic solutions in normal tension glaucoma patients.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Seoul National University Hospital
• Treatments: Brimonidine Tartrate; Brimonidine Tartrate, Timolol Maleate Drug Combination; Ophthalmic Solutions; Timolol

Criteria

Inclusion Criteria:

• over 18 years old

• baseline IOP under 22 mmHg,both anterior chamber angle > Grade 3~4 by Shaffer grading system

Exclusion Criteria:

• IOP over 22 mmHg by Goldmann applanation tonometer

• other types of glaucoma except open angle

• other IOP lowering treatment

• chronic or recurrent Hx. of ocular inflammation

• using contact lens

• any other ocular disease that could affect visual field examination (diabetic retinopathy, macular disease, uveitis, scleritis, optic neuritis, anterior ischemic optic neuropathy)

• intraocular or glaucoma surgery within 6 months

• Hx. of allergic reaction to timolol or brimonidine

• bronchial asthma

• moderate to severe chronic obstructive pulmonary disease

• heart failure

• 2~3 degree A-V block,

• MAO inhibitor use

• anti depressant use

• untreated pheochromocytoma

• pregnant